All the news Showing 10 of 44 articles from: Genotype 1bGet an RSS feed of these articles Show All news infohep newsEditors' picks from other sources China FDA Approves Country’s First All-Oral Regimen for Chronic Hepatitis C, Daklinza® (daclatasvir) in Combination with Sunvepra® (asunaprevir) Bristol-Myers Squibb / 02 May 2017 Exviera, Viekirax regimen shows high SVR in HCV genotype 1b after 8 weeks Healio / 26 September 2016 AbbVie receives CHMP positive opinion for VIEKIRAX® + EXVIERA® without ribavirin for the treatment of HCV in GT1b patients with compensated cirrhosis in Europe AbbVie press release / 02 March 2016 U.S. FDA Approves Expanded Use of Bristol-Myers Squibb’s Daklinza (daclatasvir) for Additional Challenging-to-treat Patients with Genotype 1 or Genotype 3 Chronic Hepatitis C Bristol-Myers Squibb press release / 08 February 2016 Merck Throws a Wrench in Drug Pricing Bloomberg / 01 February 2016 Zepatier for hepatitis C approved in Canada CATIE / 01 February 2016 Merck Receives FDA Approval of ZEPATIER™ (elbasvir and grazoprevir) for the Treatment of Chronic Hepatitis C Virus Genotype 1 or 4 Infection in Adults Merck press release / 29 January 2016 FDA Grants Priority Review to AbbVie for Supplemental New Drug Application for VIEKIRA PAK® without Ribavirin in Genotype 1b Compensated Cirrhosis AbbVie press release / 11 January 2016 Mylan Launches Generic Harvoni® (Ledipasvir/Sofosbuvir) Under the Brand Name MyHep LVIR™ in India Mylan press release / 08 January 2016 AbbVie Announces FDA Acceptance of New Drug Application for a Once-Daily Formulation of VIEKIRA PAK® AbbVie press release / 02 December 2015 ← First12345Next → Other pages in this section Latest news All the news Hepatitis A Hepatitis B Hepatitis C Hepatitis D Hepatitis E Coronavirus NAFLD Treatment for hepatocellular carcinoma Transmission, epidemiology and prevention Health services, policy and advocacy Social issues Conference news Email bulletin archive